• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Technology Events 2023-2024
  • Sponsored Post
    • Make a Contribution
  • Technology Jobs
  • Technology Markets
    • Venture Capital
  • About
  • Contact

23andMe Granted the First and Only FDA Authorization For Direct-to-Consumer Pharmacogenetic Reports

November 1, 2018 By admin Leave a Comment

The decision allows 23andMe to report directly to customers, without a prescription, the influence their genetics have on how well they metabolize certain medications

In another first, the U.S. Food and Drug Administration (FDA) granted 23andMe de novo authorization to offer reports on pharmacogenetics, indicating how customers’ genetics may influence the way they metabolize certain medications.

This is the first authorization of a direct-to-consumer report on pharmacogenetics and came through the FDA’s de novo classification process. With this authorization, the FDA has classified these direct-to-consumer pharmacogenetic reports as moderate risk that have special controls to ensure safety, effectiveness and accuracy. This authorization enables 23andMe to report on numerous variants associated with pharmacogenetic response.

“We’ve continued to innovate through the FDA and pioneer safe, effective pathways for consumers to directly access genetic health information,” said 23andMe co-founder and CEO Anne Wojcicki. “Pharmacogenetic reports are an important category of information for consumers to get access to and I believe this authorization opens the door for consumers to work with their health providers to better manage their medications.”

As part of the authorization process 23andMe had to demonstrate the accuracy of its testing and consumer comprehension of the testing information, including “treatment adherence” and whether or not a customer would continue their prescribed treatment of a medication, or change or stop treatment. Studies showed that more than 97 percent of users understood that they should not use the report to make any changes to treatment without consulting their doctor.

The authorization allows for the reporting of variants in multiple genes that impact how well an individual metabolizes certain medications, for example clopidogrel, which is commonly prescribed to prevent heart attacks and strokes. These genes are associated with response to more than 50 other commonly prescribed and over-the-counter medications. The authorization allows 23andMe to provide customers with information on whether they are predicted to be fast or slow metabolizers based on their genetics, and when supported by appropriate clinical evidence, whether they may experience reduced efficacy or have an increased chance of side effects from certain medications.

It has long been established that genetics influence how people respond to different medications. Certain medications have for many years included labeling with pharmacogenetics information — the FDA started listing these in 2009 — but patients often only learn that they process a medication differently after they begin taking it.

“We believe it’s important that all consumer genetic health tests should be going through the FDA and subject to the same rigorous testing that 23andMe undergoes,” said Wojcicki. “It is concerning that the FDA is not requiring all direct-to-consumer genetic testing services to meet the high bar for analytical validity, accuracy or user comprehension, which 23andMe does. It’s confusing for consumers that this double standard exists.”

This latest FDA authorization follows several years of work by 23andMe that has led to four separate FDA de novo authorizations for direct-to-consumer genetic tests for carrier status, genetic health risk reports, select BRCA1 and BRCA2 variants and now pharmacogenetic reports. Each has included an extensive FDA review process in which 23andMe was required to submit studies demonstrating that our reports are scientifically valid and understandable for consumers, and that the results are analytically reliable. In order to demonstrate this, 23andMe showed its tests have greater than 99 percent accuracy. Further, 23andMe had to demonstrate at least 90 percent user comprehension of the key concepts communicated in the reports.

Finally, the decision continues the commitment made by 23andMe to return all the types of genetic health information to customers that it offered prior to an FDA warning letter in 2013. However, 23andMe has not determined when it will be able to make these new reports available to its customers.

About 23andMe
23andMe, Inc. is the leading consumer genetics and research company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome. The company was named by MIT Technology Review in its “50 Smartest Companies, 2017” list, and featured as Fast Company’s #2 Most Innovative Health Company in 2018. 23andMe has millions of customers worldwide, with more than 80 percent of customers consented to participate in research. 23andMe, Inc. is located in Mountain View, CA. More information is available at www.23andMe.com.

SOURCE 23andMe, Inc.

Related Links
http://www.23andMe.com

Filed Under: Tech

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

China’s Poaching of Water Technologies from the West: A Serious Concern
Market Scenario of China Banning Exports of Rare Earth Materials and Electric Batteries
Navigating Markets through a 4-Dimensional Research Data Model
A Markov Chain-Based Approach for Forecasting Emerging Technologies: An Extended Analysis
Identifying Resilient Stocks Poised for a Strong Comeback Amidst Economic Recovery
China’s Debt Problem: A Looming Crisis
The Future of Travel: A $15.5 Trillion Industry

Market Research Media

The Evolution of RSS Feeds: A Media Analyst’s Perspective
AI-Enhanced 4-Dimensional Market Dynamics Analysis: Unveiling Trends, Segmentation, Behavior, and Evolution through Markov Chain Modeling
Autotutoring Market: Personalized Learning and Technological Innovation at the Forefront
Integration of Generative AI and Large Language Models for Enterprises
The Decline of Chinese Media Under Authoritarian Rule: Economic Implications
Algorithmic Bias in Media Recommendation Systems: Unveiling Challenges and Pursuing Fairness
U.S. Federal IT Market Forecast

Secondary Sidebar

Tech Events

Imagine 2023, Edge AI Conference, September 27, 2023, Computer History Museum, Mountain View, California
Microsoft Ignite, November 14-17, 2023, Seattle
Intel® Innovation 2023, September 19-20 2023, San Jose McEnery Convention Center, San Jose, California
Dreamforce 2023, September 12–14, 2023, Moscone Center, San Francisco
AI Hardware & Edge AI Summit, September 12-14, 2023, Santa Clara Marriott, Santa Clara, California

Venture Capital

Techstars and The Ohio State University Partner to Boost Software Startups in Columbus
Atlys Secures $12M to Revolutionize Visa Processing and Travel Experience
Afterparty Raises $5 Million Funding to Revolutionize Creator-Fan Interactions with Afterparty AI
Elevator Pitch: BornIntoLuxury.com (Born Into Luxury)
JETRO’s Global Startup Acceleration Program: Fueling Japanese Startups’ Global Expansion

Footer

Recent Posts

  • Bridging the Semiconductor Workforce Gap: Intel’s Innovative Educational Initiatives
  • German Government and Bavaria Invest €300M in ams OSRAM Semiconductor Tech
  • Innovative Ship Concept: Providing Zero-Carbon Nuclear Energy for Defense and Disaster Relief
  • Linux Foundation Launches OpenTofu: A New Open Source Alternative to Terraform
  • Introducing the NETGEAR Nighthawk Tri-Band Mesh WiFi 6E System: Exceptional Range and Performance for the Modern Home
  • Apple unveils iPhone 15 Pro and iPhone 15 Pro Max
  • The Future of Technology: 8 Trends to Watch in 2023
  • Reservoir Computing: Shaping the Future of AI
  • Wi-Fi HaLow: Revolutionizing IoT Connectivity with Long-Range Efficiency
  • Media and Technology: Crafting the Saga of Modernity through Innovation and Connectivity

App Coding

Creating an app that generates a description of an image using ChatGPT
Mastering the Art of Mobile App Coding: Best Practices and Tips
Tips for Writing Efficient Code
Comparison of Design Principles: Mobile Apps vs. Desktop Software
The Most In-Demand Coding Skills for Freelancers: A Guide

API Coding

API Security Guide
Quantitative Analysis Criteria for Assessing API Performance and Quality
GSMA Launches Open Gateway Initiative to Provide Universal Access to Mobile Network APIs for Developers
How to code an API with ChatGPT
Join Our Team as an API Coder - Power Cutting-Edge API Apps

Blockchaining

Building a Secure and Decentralized Blockchain API: A Step-by-Step Guide
What is NFT?
Fintech Revolution Just Started
Discontinuation of TradeLens: The End of a Blockchain-Enabled Global Trade Platform by Maersk and IBM
Exploring the Latest Innovations in Blockchain and Crypto: A Report from the European Blockchain Convention 2023

Calendarial

SBC Summit 2024, September 24-26, 2024, Lisbon, Portugal
AppCoding.com Unveils Innovative Software Products and Solutions at IBC 2023
Collaborate 2023, Unlocking Modern Work Efficiency, November 8-9, 2023
The National Day of Catalonia, Monday, September 11, 2023
World Health Summit 2023, October 15-17, 2023, Berlin, Germany

Copyright © 2022 Technologies.org

Media Partners: Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT